Sign Up Today and Learn More About Affinia Therapeutics Stock
Invest in or calculate the value of your shares in Affinia Therapeutics or other pre-IPO companies through EquityZen's platform.
Affinia Therapeutics Stock
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.
About Affinia Therapeutics Stock
Founded
2019
Headquarters
Waltham, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Affinia Therapeutics Press Mentions
Stay in the know about the latest news on Affinia Therapeutics
Affinia receives FDA fast track designation for AFTX-201
pharmaceutical-technology • Mar 06, 2026
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
businesswire • Mar 04, 2026
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)
biospace • Mar 04, 2026
Affinia’s AFTX-201 designated EU orphan drug
bioworld • Feb 20, 2026
Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)
businesswire • Feb 18, 2026
Affinia Therapeutics Management
Leadership team at Affinia Therapeutics
Board Member
Robert Weisskoff
Board Member
David Grayzel
Join now and verify your accreditation status to gain access to:
- Affinia Therapeutics Current Valuation
- Affinia Therapeutics Stock Price
- Affinia Therapeutics Management
- Available deals in Affinia Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Affinia Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Affinia Therapeutics Revenue and Financials
- Affinia Therapeutics Highlights
- Affinia Therapeutics Business Model
- Affinia Therapeutics Risk Factors
- Affinia Therapeutics Research Report from SACRA Research
Trading Affinia Therapeutics Stock
How to invest in Affinia Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Affinia Therapeutics through EquityZen funds. These investments are made available by existing Affinia Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Affinia Therapeutics stock?
Shareholders can sell their Affinia Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."